Pediatric acute myeloid leukemia (AML) is a rare disease with roughly 500 cases diagnosed in the United States each year and has had minimal improvement in clinical outcomes over recent decades. Novel treatment development to improve outcomes may be enhanced with an accompanying test for predicting treatment response.

External Link:

https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.15_suppl.10032